Recent studies suggest an association between HCV infection and cardiovascular damage, including carotid atherosclerosis, with a possible effect of HCV clearance on cardiovascular outcomes. We aimed to examine whether HCV eradication by direct antiviral agents (DAA) improves carotid atherosclerosis in HCV-infected patients with advanced fibrosis/compensated cirrhosis.
Petta, S., Adinolfi, L.E., Fracanzani, A.L., Rini, F., Caldarella, R., Calvaruso, V., et al. (2018). Hepatitis C Virus Eradication by Direct Antiviral Agents Improves Carotid Atherosclerosis in patients with Severe Liver Fibrosis. JOURNAL OF HEPATOLOGY, 69(1), 18-24 [10.1016/j.jhep.2018.02.015].
Hepatitis C Virus Eradication by Direct Antiviral Agents Improves Carotid Atherosclerosis in patients with Severe Liver Fibrosis
Petta, Salvatore
;Rini, Francesca;Caldarella, Rosalia;Calvaruso, Vincenza;Cammà, Calogero;Ciaccio, Marcello;Di Marco, Vito;Grimaudo, Stefania;Licata, Anna;Pipitone, Rosaria Maria;Pinto, Antonio;Torres, Daniele;Tuttolomondo, Antonino;Craxì, Antonio
2018-01-01
Abstract
Recent studies suggest an association between HCV infection and cardiovascular damage, including carotid atherosclerosis, with a possible effect of HCV clearance on cardiovascular outcomes. We aimed to examine whether HCV eradication by direct antiviral agents (DAA) improves carotid atherosclerosis in HCV-infected patients with advanced fibrosis/compensated cirrhosis.
| File | Dimensione | Formato | |
|---|---|---|---|
|
PETTA S ET JHEP 2018.pdf
accesso aperto
Tipologia:
Post-print
Dimensione
1.27 MB
Formato
Adobe PDF
|
1.27 MB | Adobe PDF | Visualizza/Apri |
|
Hepatitis C virus eradication by direct-acting antiviralagents improves carotid atherosclerosis in patientswith severe liver fibrosis.pdf
Solo gestori archvio
Tipologia:
Versione Editoriale
Dimensione
657.04 kB
Formato
Adobe PDF
|
657.04 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
